Literature DB >> 169281

Effects of progestins on estradiol receptor levels in human endometrium.

L Tseng, E Gurpide.   

Abstract

Medroxyprogesterone acetate (Provera) was administered orally during 2-4 days to women undergoing endometrial curettage during the follicular phase of the menstrual cycle. Estradiol (E2) receptor levels were estimated from the amounts of 2H-E2 tightly bound in nuclei after incubation of endometrial tissue with an excess of the labeled hormone. An average value (9 subjects) of 1.5 pmole E2/mg DNA +/- 0.7 (mean +1- SD) was found. This value is significantly lower than the average E2 receptor levels in proliferative endometrium of untreated subjects (3.2 +/- 1.3, n = 33) and equals the level observed in the early secretory phase (1.5 +/- 0.5, n = 5). These results indicate that one of the progestin effects on human endometrium is the reduction of E2 receptor levels.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 169281     DOI: 10.1210/jcem-41-2-402

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

Review 1.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

2.  Biomarkers of progestin therapy resistance and endometrial hyperplasia progression.

Authors:  Kristen Upson; Kimberly H Allison; Susan D Reed; Carolyn D Jordan; Katherine M Newton; Elizabeth M Swisher; Jennifer A Doherty; Rochelle L Garcia
Journal:  Am J Obstet Gynecol       Date:  2012-05-16       Impact factor: 8.661

3.  Screening for endometrial cancer.

Authors:  J A Nisker
Journal:  Can Fam Physician       Date:  1983-05       Impact factor: 3.275

4.  [Mechanisms of action of estrogens physiological and pharmacological aspects of hormonal "receptivity". The anti-estrogens (author's transl)].

Authors:  E E Baulieu
Journal:  Klin Wochenschr       Date:  1978-07-15

5.  Difference between R5020 and the antiprogestin RU486 in antiproliferative effects on human breast cancer cells.

Authors:  P G Gill; F Vignon; S Bardon; D Derocq; H Rochefort
Journal:  Breast Cancer Res Treat       Date:  1987-10       Impact factor: 4.872

6.  Contribution to the pathogenesis of dysmenorrhea.

Authors:  H P Zahradnik; M Breckwoldt
Journal:  Arch Gynecol       Date:  1984

7.  Effect of oral high-dose progestins on the disposition of antipyrine, digitoxin, and warfarin in patients with advanced breast cancer.

Authors:  S Lundgren; S Kvinnsland; E Utaaker; O Bakke; P M Ueland
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 8.  Heat shock proteins in human endometrium throughout the menstrual cycle.

Authors:  S Tabibzadeh; J Broome
Journal:  Infect Dis Obstet Gynecol       Date:  1999

9.  Influence of tamoxifen-medroxyprogesterone sequential therapy on estrogen and progesterone receptor contents of breast cancer.

Authors:  S Noguchi; H Yamamoto; H Inaji; S Imaoka; H Koyama
Journal:  Jpn J Cancer Res       Date:  1989-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.